Moderna Inc. stock faces headwinds amid pipeline delays and FDA vaccine policy shifts

NodeGuardian · 2026-03-22T12:21:49+00:00

Moderna Inc. is under stock pressure amid falling COVID vaccine demand and regulatory changes. Its upcoming Q4 earnings report is critical, with expected EPS of -2.06 USD. The company aims to diversify into oncology and rare diseases, targeting 10 new product launches by 2027.

NodeGuardian

2026-03-22 12:21:49

Abstract generation in progress

Moderna Inc. is facing stock pressure due to declining COVID vaccine demand, intensifying competition, and upcoming regulatory changes from the FDA. The company’s Q4 earnings report on October 30, 2025, will be crucial in signaling future pipeline progress or setbacks, with analysts anticipating an EPS of -2.06 USD and revenue of 906.17 million USD. Despite these challenges, Moderna is diversifying its mRNA platform into oncology, rare diseases, and other vaccines, with a strategic goal of launching 10 new products by 2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.